ethyl 7-[(4-chlorophenyl)methoxy]quinoline-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: ethyl 7-[(4-chlorophenyl)methoxy]quinoline-3-carboxylate
• 英文别名: Ethyl 7-[(4-chlorophenyl)methoxy]quinoline-3-carboxylate
• 化学式: C₁₉H₁₆ClNO₃
• 分子量: 341.794
• InChiKey: BBDQTYFWMGQAFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  7-甲氧基-3-喹啉羧酸乙酯 在 硫酸 、 氢溴酸 、 caesium carbonate 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 88.5h， 生成 ethyl 7-[(4-chlorophenyl)methoxy]quinoline-3-carboxylate
  参考文献：
  名称：

  US2014/275548

  摘要：

  公开号：

文献信息

• SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS
  申请人：DART NEUROSCIENCE, LLC

  公开号：US20140315944A1

  公开（公告）日：2014-10-23

  The invention provides a chemical entity of Formula (I) wherein R 1 , R 2 , R 3 , Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting MAO, and MAO-B selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.

  该发明提供了化学实体公式（I），其中R1、R2、R3、Y和n具有此处描述的任何值，以及包含这种化学实体的组合物；制造它们的方法；以及它们在广泛的方法中的用途，包括代谢和反应动力学研究、检测和成像技术、放射性治疗和治疗，包括抑制MAO和MAO-B选择性，增强神经可塑性，治疗神经系统疾病，提供神经保护，治疗与中枢神经系统疾病相关的认知障碍，增强认知和运动训练的效率，提供神经恢复和神经康复，增强非人类动物训练协议的效率，以及治疗外周疾病（包括肥胖症、糖尿病和心血管代谢紊乱）及其相关的共病。
• Substituted naphthyridine and quinoline compounds as MAO inhibitors
  申请人：DART NEUROSCIENCE (CAYMAN) LTD.

  公开号：US09102674B2

  公开（公告）日：2015-08-11

  The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, Y, and n have any of the values described herein and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies, detection and imaging techniques, and radioactive treatments; and therapies, including inhibiting MAO, and MAO-B selectively, enhancing neuronal plasticity, treating neurological disorders, providing neuroprotection, treating a cognitive impairment associated with a CNS disorder, enhancing the efficiency of cognitive and motor training, providing neurorecovery and neurorehabilitation, enhancing the efficiency of non-human animal training protocols, and treating peripheral disorders (including obesity, diabetes, and cardiometabolic disorders) and their associated co-morbidities.

  本发明提供了化学实体式为(I)的化学实体，其中R1、R2、R3、Y和n具有此处描述的任何值，以及包含这种化学实体的组合物；制备它们的方法；以及它们在广泛的方法中的使用，包括代谢和反应动力学研究、检测和成像技术、放射性治疗和治疗方法，包括抑制MAO和选择性抑制MAO-B、增强神经可塑性、治疗神经系统疾病、提供神经保护、治疗与中枢神经系统疾病相关的认知障碍、增强认知和运动训练的效率、提供神经恢复和神经康复、增强非人类动物训练方案的效率，并治疗外周疾病（包括肥胖症、糖尿病和心血管代谢疾病）及其相关的共病症。
• US20140275548A1
  申请人：——

  公开号：——

  公开（公告）日：——
• MAO-B INHIBITORS AND REHABILITATION
  申请人：DART NEUROSCIENCE (CAYMAN) LTD.

  公开号：US20170273968A1

  公开（公告）日：2017-09-28

  Methods of rehabilitation of neurological disorders, including neurological deficits associated with neurotraumas, such as stroke and traumatic brain injury, and with muscle disorders, that includes administering to a subject a MAO-B inhibitor.
• US9102674B2
  申请人：——

  公开号：US9102674B2

  公开（公告）日：2015-08-11